Despite exerting strong antitumor activity in a variety of human experimental cancers and possessing higher binding affinity for their receptors compared with earlier GHRH antagonists, MIA-602 and MIA-690 display a weak inhibitory effect on GH release [17]. The gene discussed is GHRH; the disease is cancer.